Adaptimmune Reports Q2 Financial Results and Business Update
– Reported responses in multiple solid tumor types during ASCO with updates at upcoming congresses in Q4 –– Continued progress […]
Alico, Inc. Announces Two New Appointments to the Board of Directors
FORT MYERS, Fla., Aug. 06, 2020 (GLOBE NEWSWIRE) — Alico, Inc. (“Alico” or the “Company”) (Nasdaq: ALCO) today announces the […]
Intellia Therapeutics Announces Second Quarter 2020 Financial Results
Submitted first regulatory application to the U.K.’s MHRA to initiate a Phase 1 study of NTLA-2001 for the treatment of […]
Eloxx Pharmaceuticals Reports Second Quarter 2020 Financial and Operating Results and Provides Business Update
Enrollment in our Phase 2 clinical trial program for ELX-02 in cystic fibrosis has been resumed in Europe and Israel […]
Selecta Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Updates
Closed strategic licensing agreement with Sobi for SEL-212 for $100 million in initial payments and up to $630 million in […]
Kelly® Reports Second Quarter Earnings
Financial HighlightsQ2 revenue declined 28.7% or 27.7% in constant currencyQ2 operating earnings of $11.1 million, down 68.2%, or down 50.4% […]
TSX News -
Cronos Group Reports 2020 Second Quarter Results
Cronos Israel commenced the sale of PEACE NATURALS™ products to the Israeli medical cannabis marketNatuera completed three additional test exports of […]
TSX News -
Aptose Biosciences to Present at Canaccord Genuity 40th Annual Growth Conference
SAN DIEGO and TORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company […]
TSX News -
IBI Group Plays Major Design Role on Broadway Subway Expansion as Part of Acciona-Ghella Preferred Proponent Joint Venture
TORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) — IBI Group (TSX:IBG) is part of the Acciona-Ghella Joint Venture (AGJV), the preferred […]
TSX News -
Notice of Knight Therapeutics’ Second Quarter 2020 Results Conference Call
MONTREAL, Aug. 06, 2020 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, […]
